Celcuity (CELC) Income from Continuing Operations (2016 - 2025)
Celcuity (CELC) reported Income from Continuing Operations of 50973000.0 for Q4 2025, down 39.07% on a YoY basis from 83657071.11 in Q4 2024, and down 16.37% quarter-over-quarter from 43804000.0 in Q3 2025.
Celcuity (CELC) Income from Continuing Operations (2016 - 2025) Analysis & Trends
Celcuity has reported Income from Continuing Operations for 10 years, with the latest figure at 50973000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 39.07% year-over-year to 50973000.0; the trailing twelve-month figure through Dec 2025 stood at 177042000.0 (down 58.39% YoY), and the FY2025 full-year result was 177042000.0, down 58.39% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 50973000.0, down from 43804000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2791668.0 in Q1 2021, with the low at 50973000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 21128771.1 across 5 years, with a median of 16496113.5 in 2023.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 537.28% — and 2022, when it rose 29.02%.
- Celcuity's Income from Continuing Operations stood at 6753500.0 in 2021, then plunged by 71.49% to 11581346.0 in 2022, then slumped by 62.75% to 18848472.0 in 2023, then plunged by 94.46% to 36653000.0 in 2024, then plunged by 39.07% to 50973000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 50973000.0 (Q4 2025), 43804000.0 (Q3 2025), and 45268000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | -50.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50.97 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -45.27 Mn |
| Mar 31, 2025 | -37.00 Mn |
| Dec 31, 2024 | -36.65 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -23.72 Mn |
| Mar 31, 2024 | -21.61 Mn |
| Dec 31, 2023 | -18.85 Mn |
| Sep 30, 2023 | -18.40 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | -11.94 Mn |
| Dec 31, 2022 | -11.58 Mn |
| Sep 30, 2022 | -10.89 Mn |
| Jun 30, 2022 | -9.96 Mn |
| Mar 31, 2022 | -7.93 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -6.03 Mn |
| Jun 30, 2021 | -14.03 Mn |
| Mar 31, 2021 | -2.79 Mn |